Moomoo AIのまとめ
On September 30, 2024, a group of related entities including GV 2019, L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., GV 2021, L.P., GV 2021 GP, L.P., GV 2021 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc., collectively known as the Reporting Persons, filed an amendment with the United States Securities and Exchange Commission to report that they have ceased to be beneficial owners of more than 5% of Invivyd, Inc.'s common stock. This amendment, identified as Schedule 13G/A, indicates that as of September 30, 2024, the Reporting Persons collectively own 0.0% of Invivyd's issued common stock, which is calculated based on 119,442,635 shares outstanding as of August 1, 2024. The initial statement was filed on February 14, 2022, and this recent amendment confirms the change in ownership status. Invivyd, Inc., formerly known as Adagio Therapeutics, Inc., is headquartered in Waltham, MA, and the Reporting Persons are associated with entities organized in Delaware, with a principal business office located at 1600 Amphitheatre Parkway, Mountain View, CA.
On September 30, 2024, a group of related entities including GV 2019, L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., GV 2021, L.P., GV 2021 GP, L.P., GV 2021 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc., collectively known as the Reporting Persons, filed an amendment with the United States Securities and Exchange Commission to report that they have ceased to be beneficial owners of more than 5% of Invivyd, Inc.'s common stock. This amendment, identified as Schedule 13G/A, indicates that as of September 30, 2024, the Reporting Persons collectively own 0.0% of Invivyd's issued common stock, which is calculated based on 119,442,635 shares outstanding as of August 1, 2024. The initial statement was filed on February 14, 2022, and this recent amendment confirms the change in ownership status. Invivyd, Inc., formerly known as Adagio Therapeutics, Inc., is headquartered in Waltham, MA, and the Reporting Persons are associated with entities organized in Delaware, with a principal business office located at 1600 Amphitheatre Parkway, Mountain View, CA.
2024年9月30日、GV 2019、L.P.、GV 2019 GP、L.P.、GV 2019 GP、L.L.C.、GV 2021、L.P.、GV 2021 GP、L.P.、GV 2021 GP、L.L.C.、Alphabet Holdings LLC、XXVI Holdings Inc.、およびAlphabet Inc.などを含む一連の関連エンティティ（以下、報告者としても知られる）は、アメリカ証券取引委員会に修正報告書を提出し、Invivyd, Inc.の普通株式の5%以上を所有していないことを報告しました。 この修正報告書であるスケジュール13G/Aは、2024年9月30日時点で、報告者...すべて展開
2024年9月30日、GV 2019、L.P.、GV 2019 GP、L.P.、GV 2019 GP、L.L.C.、GV 2021、L.P.、GV 2021 GP、L.P.、GV 2021 GP、L.L.C.、Alphabet Holdings LLC、XXVI Holdings Inc.、およびAlphabet Inc.などを含む一連の関連エンティティ（以下、報告者としても知られる）は、アメリカ証券取引委員会に修正報告書を提出し、Invivyd, Inc.の普通株式の5%以上を所有していないことを報告しました。 この修正報告書であるスケジュール13G/Aは、2024年9月30日時点で、報告者はInvivydの発行済み普通株式の0.0%を合計して所有しており、これは2024年8月1日時点での119,442,635株の発行済み株式に基づいて計算されています。 初期の報告書は2022年2月14日に提出され、この最近の修正は所有権の変更を確認しています。 Invivyd, Inc.（以前のAdagio Therapeutics, Inc.）はマサチューセッツ州ウォルサムに本部を置き、報告者はデラウェア州で組織されたエンティティと関連しており、本社はカリフォルニア州マウンテンビューの1600 Amphitheatre Parkwayに位置しています。
役に立った
役に立たない
